MX2019003545A - Compuestos heterociclicos y uso de los mismos para prevenir o tratar infecciones bacterianas. - Google Patents

Compuestos heterociclicos y uso de los mismos para prevenir o tratar infecciones bacterianas.

Info

Publication number
MX2019003545A
MX2019003545A MX2019003545A MX2019003545A MX2019003545A MX 2019003545 A MX2019003545 A MX 2019003545A MX 2019003545 A MX2019003545 A MX 2019003545A MX 2019003545 A MX2019003545 A MX 2019003545A MX 2019003545 A MX2019003545 A MX 2019003545A
Authority
MX
Mexico
Prior art keywords
preventing
heterocyclic compounds
bacterial infections
treating bacterial
treating
Prior art date
Application number
MX2019003545A
Other languages
English (en)
Inventor
Chasset Sophie
Chevreuil Francis
Barbion Julien
Brias Julie
Caravano Audrey
Faivre Fabien
Vomscheid Sophie
Simon Christophe
Lecointe Nicolas
Ledoussal Benoît
Richard Sébastien
Le Fralliec Géraldine
Oliveira Chrystelle
Lebel Rémi
Le-Strat Frédéric
Farescour Laurence
Original Assignee
Mutabilis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mutabilis filed Critical Mutabilis
Publication of MX2019003545A publication Critical patent/MX2019003545A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La invención se refiere a un compuesto de fórmula (I) y un racemato, un enantiómero, un diastereoisómero, un isómero geométrico o una sal farmacéuticamente aceptable y su uso como agente antibacteriano.
MX2019003545A 2016-09-30 2017-09-29 Compuestos heterociclicos y uso de los mismos para prevenir o tratar infecciones bacterianas. MX2019003545A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306261.5A EP3301094A1 (en) 2016-09-30 2016-09-30 Heterocyclic compounds and their use in preventing or treating bacterial infections
PCT/EP2017/074873 WO2018060481A1 (en) 2016-09-30 2017-09-29 Heterocyclic compounds and their use in preventing or treating bacterial infections

Publications (1)

Publication Number Publication Date
MX2019003545A true MX2019003545A (es) 2019-06-17

Family

ID=57130331

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003545A MX2019003545A (es) 2016-09-30 2017-09-29 Compuestos heterociclicos y uso de los mismos para prevenir o tratar infecciones bacterianas.

Country Status (24)

Country Link
US (1) US10722520B2 (es)
EP (3) EP3301094A1 (es)
JP (2) JP7089508B2 (es)
KR (1) KR20190065326A (es)
CN (2) CN109906226B (es)
AR (1) AR109774A1 (es)
AU (1) AU2017335222C1 (es)
BR (1) BR112019006371A2 (es)
CA (1) CA3038221A1 (es)
CL (1) CL2019000857A1 (es)
DK (1) DK3519411T3 (es)
ES (1) ES2927528T3 (es)
HR (1) HRP20220831T1 (es)
HU (1) HUE059938T2 (es)
IL (1) IL265676B (es)
LT (1) LT3519411T (es)
MX (1) MX2019003545A (es)
PL (1) PL3519411T3 (es)
PT (1) PT3519411T (es)
RS (1) RS63473B1 (es)
SI (1) SI3519411T1 (es)
TW (1) TWI801353B (es)
WO (1) WO2018060481A1 (es)
ZA (1) ZA201901963B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
CA3120371A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
JP2024503893A (ja) * 2021-01-21 2024-01-29 エヌフレクション セラピューティクス インコーポレイテッド ピロロピリジン－アニリン化合物を調製するための方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
AU2005273619B2 (en) * 2004-08-18 2009-05-28 Pfizer Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
US8138189B2 (en) 2009-03-26 2012-03-20 Hoffman-La Roche Inc. Substituted benzene compounds as modulators of the glucocorticoid receptor
TW201319068A (zh) * 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
US8791091B2 (en) * 2011-12-02 2014-07-29 Bristol-Myers Squibb Company Aryl dihydropyridinone and piperidinone MGAT2 inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
US9487474B2 (en) 2012-06-04 2016-11-08 Elkimia, Inc. Imino compounds as protecting agents against ultraviolet radiations
WO2014102759A2 (en) 2012-12-31 2014-07-03 Ranbaxy Laboratories Limited Process for the preparation of dasatinib and its intermediates
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
US20140315876A1 (en) * 2013-03-15 2014-10-23 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN107980000A (zh) * 2014-04-18 2018-05-01 沃克哈特有限公司 包含抗菌剂的药物组合物
RS58429B1 (sr) * 2014-11-17 2019-04-30 Entasis Therapeutics Ltd Kombinovana terapija za lečenje rezistentnih bakterijskih infekcija
CN105704828A (zh) * 2014-11-25 2016-06-22 中兴通讯股份有限公司 一种资源调度的方法和装置
JP6767392B2 (ja) * 2015-05-07 2020-10-14 ミュタビリスＭｕｔａｂｉｌｉｓ 複素環式化合物及び細菌感染の治療又は予防におけるその使用
EP3091018A1 (en) * 2015-05-07 2016-11-09 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections

Also Published As

Publication number Publication date
PL3519411T3 (pl) 2022-08-22
EP3301094A1 (en) 2018-04-04
SI3519411T1 (sl) 2022-08-31
HRP20220831T1 (hr) 2022-09-30
EP3519411B1 (en) 2022-06-22
PT3519411T (pt) 2022-08-25
CL2019000857A1 (es) 2019-08-09
RU2019109177A3 (es) 2020-11-30
AU2017335222A1 (en) 2019-04-11
JP2019530690A (ja) 2019-10-24
KR20190065326A (ko) 2019-06-11
DK3519411T3 (da) 2022-07-11
US20190224210A1 (en) 2019-07-25
HUE059938T2 (hu) 2023-01-28
US10722520B2 (en) 2020-07-28
EP4086255A1 (en) 2022-11-09
ZA201901963B (en) 2021-01-27
CN109906226A (zh) 2019-06-18
AU2017335222B2 (en) 2021-07-15
IL265676A (en) 2019-05-30
CA3038221A1 (en) 2018-04-05
CN113929680A (zh) 2022-01-14
RS63473B1 (sr) 2022-08-31
TW201815791A (zh) 2018-05-01
LT3519411T (lt) 2022-09-12
TWI801353B (zh) 2023-05-11
EP3519411A1 (en) 2019-08-07
JP7089508B2 (ja) 2022-06-22
AU2017335222A2 (en) 2019-05-09
JP2022097520A (ja) 2022-06-30
AU2017335222C1 (en) 2022-01-20
AR109774A1 (es) 2019-01-23
IL265676B (en) 2021-12-01
RU2019109177A (ru) 2020-09-30
WO2018060481A1 (en) 2018-04-05
BR112019006371A2 (pt) 2019-06-25
ES2927528T3 (es) 2022-11-08
CN109906226B (zh) 2021-11-02

Similar Documents

Publication Publication Date Title
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
UA117976C2 (uk) Сполуки амінопіримідинілу як інгібітори jak
WO2016011390A8 (en) Irak4 inhibiting agents
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2017007829A (es) Composicion antimicrobiana.
AR103680A1 (es) Inhibidores selectivos de bace1
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
EP3492468A4 (en) HETEROCYCLIC COMPOUND AS A JAK INHIBITOR, SALTS AND THERAPEUTIC USE THEREOF
MX2018014813A (es) Composiciones antibacterianas.
PH12017500290A1 (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
PH12019550154A1 (en) Azetidine derivative
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
MX2019003545A (es) Compuestos heterociclicos y uso de los mismos para prevenir o tratar infecciones bacterianas.
MX2017014080A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
PH12018500358A1 (en) Compounds for use in an antibacterial applications
MX2019006768A (es) Peptidos antimicrobianos.
PH12019502509A1 (en) Compounds and methods for treating bacterial infections
SG11201903801YA (en) Pyridone compound as c-met inhibitor
PH12020550222A1 (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
AU2016330503A8 (en) Therapeutic compounds and methods of use thereof
MY183906A (en) Fungal keratitis prophylactic or therapeutic agent
PH12020550549A1 (en) Compositions for preventing or treating lupus
PH12019500237A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
MY198328A (en) Adamantylmethylamine Derivative and use Thereof as Pharmaceutical